TB-500 is the name the research chemical market uses for a fragment of thymosin beta-4, a 43 amino acid peptide that sits in almost every cell in your body at fairly high concentration. It is one of the most abundant intracellular proteins in platelets and white blood cells. When tissue is damaged, platelets degranulate and dump thymosin beta-4 into the wound bed within minutes. That is not marketing, that is basic cell biology from the 1990s onward, and it is the honest starting point for any discussion of this compound.

What it does inside a cell

The primary job of thymosin beta-4 is actin sequestration. It binds monomeric G-actin and holds a reserve pool that the cell can release when it needs to build filaments fast. Cells that need to crawl (keratinocytes closing a wound, endothelial cells forming new vessels, fibroblasts migrating into a defect) depend on rapid actin turnover, so a peptide that regulates the available monomer pool has an obvious lever on migration speed.

Downstream of that, thymosin beta-4 has been shown to upregulate vascular endothelial growth factor, increase laminin-5 expression in keratinocytes, and suppress nuclear factor kappa B signalling, which is where the anti-inflammatory claims come from. The seven amino acid stretch responsible for most of the actin binding and cell migration activity is the LKKTETQ sequence at positions 17 to 23. Most products sold as TB-500 are either the full 43-mer or an acetylated fragment built around that active region, and this matters more than the marketing admits: they are not the same molecule and they do not necessarily behave the same way in a body.

What the animal work found

The rodent and rabbit literature is reasonably consistent. In full thickness dermal wounds in rats and mice, topical or intraperitoneal thymosin beta-4 accelerated closure and increased collagen deposition and angiogenesis compared with vehicle. In rat models of myocardial infarction, systemic and intracardiac thymosin beta-4 reduced scar volume and improved cardiac function, work led by Bock-Marquette and colleagues that got a lot of attention in 2004 because it suggested epicardial progenitor cells could be coaxed back into action. Tendon studies in rats have reported improved tensile strength in healing Achilles tendon at four weeks.

All of that is real and it is published in serious journals. It is also all rodent, and rodent wound healing is not human wound healing. Rats have a panniculus carnosus muscle layer that closes wounds by contraction in a way human skin does not. Effect sizes in rodent repair models routinely fail to survive translation.

What happened in humans

Thymosin beta-4 has been through real human trials, which is more than most peptides in this category can claim. RegeneRx ran phase 2 programmes in three areas. In dry eye disease, a 0.1 percent ophthalmic formulation showed improvement in ocular discomfort and corneal staining in a phase 2 trial and later in neurotrophic keratopathy, where several patients with persistent epithelial defects achieved full closure. That is the strongest human signal in the whole file, and it is topical, in the eye, at a dose measured in drops.

Venous stasis ulcers and epidermolysis bullosa trials were less clean. The pressure ulcer and venous ulcer work showed trends toward faster closure at some doses but did not deliver a decisive result, and the programmes did not carry through to phase 3 approval. There is no published randomised controlled trial of systemic subcutaneous thymosin beta-4 for tendon injury, muscle strain, or joint repair in humans. Every claim you see about TB-500 fixing a rotator cuff or a hamstring tear is extrapolated from rats, from mechanism, or from someone's log.

Dosing people use

The commonly circulated protocol is a loading phase of 4 to 5 mg per week, usually split into two subcutaneous injections of roughly 2 to 2.5 mg, run for four to six weeks, then a maintenance dose of 2 to 2.5 mg every one to two weeks. Some people inject near the injury site on the theory of local concentration, though thymosin beta-4 distributes systemically and the plasma half life is short, on the order of a couple of hours, so site injection is probably more ritual than pharmacology. These numbers come from vendor protocols and user reports, not from a dose-finding study. No one has established a human therapeutic window for systemic use.

Side effects and unknowns

  • Injection site reactions and transient lethargy are the most commonly reported effects, both mild and both self-reported.
  • The angiogenic mechanism is the real theoretical concern. A peptide that reliably increases VEGF expression and endothelial migration is a peptide you should not be taking if you have an undiagnosed or treated malignancy. This is not scaremongering, it is the direct implication of the mechanism, and no long-term human safety data exists to argue against it.
  • WADA has thymosin beta-4 on the prohibited list under S2. Tested athletes should treat this as disqualifying.

Where we land

Thymosin beta-4 is one of the better-characterised repair peptides in terms of mechanism, and the ocular surface data is genuinely encouraging. The gap between that and the way TB-500 is sold for musculoskeletal injury is enormous. If someone tells you the tendon evidence is solid, ask them to show you the human trial, because it has not been run.